Agios Pharmaceuticals, Inc.
AGIO
$36.16
$1.163.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 278.14% | 288.87% | 291.35% | 407.03% | -73.74% |
| Total Depreciation and Amortization | -12.03% | -9.67% | -14.65% | -19.12% | -19.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,610.41% | -1,638.81% | -1,632.94% | -1,531.80% | 183.81% |
| Change in Net Operating Assets | -82.49% | -22.55% | -3.73% | 340.60% | -4.68% |
| Cash from Operations | -32.43% | -33.49% | -31.68% | -13.61% | -2.39% |
| Capital Expenditure | -235.59% | -211.74% | -68.67% | -8.43% | -64.90% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -96.98% | -98.25% | 9.07% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.79% | -49.76% | -31.00% | 36.98% | 1.78% |
| Cash from Investing | 32.54% | 14.66% | 51.70% | 123.83% | 1.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -5.46% | 15.48% | 165.82% | 122.70% | 137.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.46% | 15.48% | 165.82% | 126.71% | 147.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,451.91% | -372.14% | 76.58% | 425.89% | 93.80% |